Xolatryp

Xolatryp is a small-molecule inhibitor specifically targeting the Transient Receptor Potential Canonical (TRPC) ion channels subtypes 3, 6, and 7.  It was developed using a rational drug discovery approach.

This innovative therapeutic candidate aims to effectively prevent cardiac damage and secondary brain injury by inhibiting excessive calcium ion accumulation, a crucial mechanism underlying cellular death and tissue injury.

The TRPC family comprises seven distinct members (TRPC1 to TRPC7), organised into four subgroups based on structural homology: TRPC1, TRPC2, TRPC4/5, and TRPC3/6/7.  Among these, the TRPC3/6/7 subfamily is broadly expressed in various tissues and exhibits increased expression levels during pathological conditions. Overactivation of these channels (TRPC3/6/7) in disease states results in excessive intracellular calcium accumulation, particularly affecting neurons and cardiomyocytes, thereby promoting cell death.

Nyrada’s preclinical studies have demonstrated that Xolatryp substantially reduced secondary brain injury by approximately 42% and offered significant cardioprotection, with an 86% improvement observed in myocardial reperfusion injury models.

Xolatryp is covered by a composition-of-matter patent application, underscoring its innovative chemical structure and promising therapeutic potential.